Eli Lilly and Company $LLY Holdings Cut by Birmingham Capital Management Co. Inc. AL

Birmingham Capital Management Co. Inc. AL trimmed its position in Eli Lilly and Company (NYSE:LLY) by 7.1% during the second quarter, Holdings Channel.com reports. The firm owned 10,330 shares of the company’s stock after selling 795 shares during the period. Eli Lilly and Company accounts for about 3.6% of Birmingham Capital Management Co. Inc. AL’s holdings, making the stock its 5th largest holding. Birmingham Capital Management Co. Inc. AL’s holdings in Eli Lilly and Company were worth $8,053,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. WestEnd Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after acquiring an additional 21 shares during the period. Wealth Preservation Advisors LLC purchased a new position in shares of Eli Lilly and Company during the 1st quarter worth about $27,000. Citizens National Bank Trust Department lifted its holdings in shares of Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after acquiring an additional 27 shares during the period. Financial Gravity Asset Management Inc. purchased a new position in shares of Eli Lilly and Company during the 1st quarter worth about $40,000. Finally, TD Capital Management LLC lifted its holdings in shares of Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after acquiring an additional 31 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Down 1.9%

Shares of NYSE:LLY opened at $803.53 on Monday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $935.63. The company has a 50 day moving average of $753.09 and a two-hundred day moving average of $765.70. The company has a market capitalization of $760.51 billion, a price-to-earnings ratio of 52.52, a price-to-earnings-growth ratio of 1.15 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter last year, the company earned $3.92 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

LLY has been the topic of several recent analyst reports. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price objective on the stock. in a report on Sunday, August 17th. Guggenheim reissued a “buy” rating and set a $948.00 target price on shares of Eli Lilly and Company in a research report on Thursday. Morgan Stanley dropped their target price on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a research report on Friday, October 3rd. UBS Group dropped their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $939.12.

Insider Buying and Selling

In other news, Director Gabrielle Sulzberger acquired 117 shares of the stock in a transaction on Tuesday, August 12th. The stock was bought at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the transaction, the director directly owned 2,703 shares of the company’s stock, valued at $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director J Erik Fyrwald acquired 1,565 shares of the stock in a transaction on Tuesday, August 12th. The stock was purchased at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director directly owned 74,578 shares of the company’s stock, valued at $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 4,514 shares of company stock valued at $2,894,841 over the last three months. Company insiders own 0.14% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.